CLINICAL TRIALS PROFILE FOR COPPER CU-64 DOTATATE
✉ Email this page to a colleague
All Clinical Trials for copper cu-64 dotatate
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT04234568 ↗ | Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors | Recruiting | National Cancer Institute (NCI) | Phase 1 | 2020-06-29 | This phase I trial studies the side effects and best dose of triapine when given together with lutetium Lu 177 dotatate in treating patients with neuroendocrine tumors. Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radioactive drugs, such as lutetium Lu 177 dotatate, may carry radiation directly to tumor cells and not harm normal cells. Giving triapine and lutetium Lu 177 dotatate together may be a good way in treating patients with neuroendocrine tumors. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for copper cu-64 dotatate
Condition Name
Clinical Trial Locations for copper cu-64 dotatate
Trials by Country
Clinical Trial Progress for copper cu-64 dotatate
Clinical Trial Phase
Clinical Trial Sponsors for copper cu-64 dotatate
Sponsor Name